BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, targeting of the N-SH2 domain of SHP2 with monobodies markedly reduces its interaction with Gab2 and has significant effects on downstream signaling in BCR/ABL-drived CML (63).